Results 1 to 10 of about 18,503 (241)

A NANOBODY molecule that blocks MerTK ectodomain cleavage in vitro and in vivo [PDF]

mAbs
The membrane receptor MerTK is critical for the resolution of inflammation and thus is of pharmacological interest. MerTK function is inhibited by the proteolytic cleavage of its extracellular domain leading to the formation of soluble Mer (sMer).
Linde Duprez, Ayse Kilic, Hélène Bruwiere, Karim Fekir, Dennis Vlaeminck, Camille De Craene, Daan Geiregat, Kirsten Paesen, Lien Leutenez, Stijn Lambrecht, Thomas Van De Velde, Aline Moliere, Judith Verhelst, Edith Stuyven, Soraya Hoelper, Dieter Schmoll   +15 more
doaj   +2 more sources

Development of novel-nanobody-based lateral-flow immunochromatographic strip test for rapid detection of recombinant human interferon α2b

Journal of Pharmaceutical Analysis, 2022
Recombinant human interferon α2b (rhIFNα2b) is widely used as an antiviral therapy agent for the treatment of hepatitis B and hepatitis C. The current identification test for rhIFNα2b is complex.
Youxue Ding, Dening Pei, Chunming Rao
exaly   +3 more sources

Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment [PDF]

Journal of Hematology & Oncology
Background CAR-T therapy is effective in hematologic cancers but faces challenges in solid tumors due to antigen heterogeneity and an immunosuppressive tumor microenvironment (TME).
Yangzi Li, Xuan Wang, Shangkun Zhang, Tao Peng, Zihan Gong, Haodong Jiang, Xianing Huang, Shenxia Xie, Heng Liu, Fengzhen Mo, Tongcun Zhang, Xiaomei Yang, Xiaobing Jiang, Xiaoling Lu   +13 more
doaj   +2 more sources

Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy

Signal Transduction and Targeted Therapy, 2021
Chimeric antigen receptor-based T-cell immunotherapy is a promising strategy for treatment of hematological malignant tumors; however, its efficacy towards solid cancer remains challenging.
Fengzhen Mo, Siliang Duan, Xiaobing Jiang, Xiaomei Yang, Xiaoqiong Hou, Wei Shi, Cueva Jumbo Juan Carlos, Aiqun Liu, Shihua Yin, Wu Wang, Hua Yao, Zihang Yu, Zhuoran Tang, Shenxia Xie, Ziqiang Ding, Xinyue Zhao, Bruce D. Hammock, Xiaoling Lu   +17 more
doaj   +1 more source

Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein [PDF]

Iranian Journal of Basic Medical Sciences, 2021
Objective(s): SLC39A6 (solute carrier family 39) or LIV-1, is a zinc-transporter protein associated with estrogen-positive breast cancer and its metastatic spread.
Hajarsadat Ghaderi, Zahra Noormohammadi, Mahdi Habibi-Anbouhi, Fatemeh Kazemi-Lomedasht, Mahdi Behdani   +4 more
doaj   +1 more source

Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein

Cells, 2022
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an infectious disease that has become a serious burden on global public health.
Qianling Su, Wei Shi, Xianing Huang, Yakun Wan, Guanghui Li, Bengang Xing, Zhi Ping Xu, Hongbo Liu, Bruce D. Hammock, Xiaomei Yang, Shihua Yin, Xiaoling Lu   +11 more
doaj   +1 more source

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Journal of Hematology & Oncology, 2023
Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang, Xiaoling Lu   +12 more
doaj   +1 more source

Recent advances of nanobody applications in diagnosis and detection

MedComm – Biomaterials and Applications, 2023
Nanobodies (Nbs) are the variable domain of heavy‐chain antibodies derived from the blood of camelids or sharks. Nanobodies are the smallest antibody fragment with intact antigen‐binding ability.
Qianling Su, Wei Shi, Xianing Huang, Shihua Yin, Xiaomei Yang, Xiaoling Lu   +5 more
doaj   +1 more source

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Journal of Immunology Research, 2020
Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited.
Lichen Zhu, Xiaomei Yang, Dani Zhong, Shenxia Xie, Wei Shi, Yangzi Li, Xiaoqiong Hou, HuaYao, Huihui Zhou, Minlong Zhao, Ziqiang Ding, Xinyue Zhao, Fengzhen Mo, Shihua Yin, Aiqun Liu, Xiaoling Lu   +15 more
doaj   +1 more source

Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function [PDF]

Iranian Journal of Basic Medical Sciences, 2018
Objective(s): Nanobodies, the single domain antigen binding fragments of heavy chain-only antibodies occurring naturally in camelid sera, are the smallest intact antigen binding entities.
Fatemeh Kazemi-Lomedasht, serge muyldermans, Mahdi Habibi-Anbouhi, Mahdi Behdani   +3 more
doaj   +1 more source